Kriya Therapeutics valuation, funding and investors

Kriya Therapeutics works in gene therapy research and development, based in Morrisville, United States. Founded in 2019, it has about 200 employees.

Biotechnology Series D

VALUATION · TODAY

$4.74B −8% after Series D

Range $2.43B – $7.31B · Grade B

TODAY

+12 MO

$2.00B

$4.00B

$6.00B

$8.00B

2020

2021

2022

2023

2024

2025

2026

2027

Series C $270M

Series D $320M

ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then

HEADCOUNT · TODAY194 employees

+3%6m growth

−4%1y growth

−3%2y growth

100

200

300

Data from Jan 2023

TODAY

Predicted in 1 yr $4.35B −8% vs today

Predicted next raise $566M if a round comes

Winding-down probability 28%

Last round: Series D · $320M · Sep 2025
Valuation at last round: $4.00B · implied
Headcount: 194 · flat
Grade: B
Founded: 2019

How VCMC values companies →

Kriya Therapeutics valuation today

VCMC values Kriya Therapeutics at $4.7B today, with a range of $2.4B to $7.3B and a grade of B. The valuation starts from its last funding round, a Series D round in Sep 2025.

Valuation by date (97 rows)

Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.

Kriya Therapeutics: valuation by date, as the model would have shown it on each date
Date	Valuation	Range	Predicted in 1 yr	Phase	Headcount	Trend	Grade	Winding-down probability
1 Jan 2019	$12.4M	$4.52M – $34.1M	$15.3M (+24%)	before first round	–	unknown	D	0%
1 Feb 2019	$12.7M	$4.64M – $35.0M	$15.5M (+21%)	before first round	–	unknown	D	0%
1 Mar 2019	$13.1M	$4.75M – $35.9M	$15.6M (+19%)	before first round	–	unknown	D	0%
1 Apr 2019	$13.4M	$4.88M – $36.8M	$15.7M (+17%)	before first round	–	unknown	D	0%
1 May 2019	$13.8M	$5.01M – $37.8M	$15.9M (+15%)	before first round	–	unknown	D	0%
1 Jun 2019	$14.1M	$5.15M – $38.8M	$16.0M (+13%)	before first round	–	unknown	D	0%
1 Jul 2019	$14.5M	$5.28M – $39.8M	$16.2M (+11%)	before first round	–	unknown	D	0%
1 Aug 2019	$14.7M	$5.33M – $40.2M	$16.3M (+11%)	before first round	–	unknown	D	0%
1 Sep 2019	$14.8M	$5.38M – $40.6M	$16.5M (+11%)	before first round	–	unknown	D	0%
1 Oct 2019	$14.9M	$5.43M – $41.0M	$16.6M (+11%)	before first round	–	unknown	D	0%
1 Nov 2019	$15.1M	$5.48M – $41.4M	$16.8M (+11%)	before first round	–	unknown	D	0%
1 Dec 2019	$15.2M	$5.53M – $41.7M	$16.9M (+11%)	before first round	–	unknown	D	0%
1 Jan 2020	$15.3M	$5.58M – $42.1M	$17.1M (+11%)	before first round	–	unknown	D	0%
1 Feb 2020	$15.5M	$5.63M – $42.5M	$17.2M (+11%)	before first round	–	unknown	D	0%
1 Mar 2020	$15.6M	$5.68M – $42.9M	$17.4M (+11%)	before first round	–	unknown	D	0%
1 Apr 2020	$15.7M	$5.73M – $43.3M	$17.5M (+11%)	before first round	–	unknown	D	0%
1 May 2020	$15.9M	$5.78M – $43.6M	$17.7M (+11%)	before first round	–	unknown	D	0%
1 Jun 2020	$16.0M	$5.84M – $44.0M	$17.9M (+11%)	before first round	–	unknown	D	0%
1 Jul 2020	$16.2M	$5.89M – $44.4M	$18.0M (+11%)	before first round	–	unknown	D	0%
1 Aug 2020	$16.3M	$5.94M – $44.8M	$18.2M (+11%)	before first round	–	unknown	D	0%
1 Sep 2020	$16.5M	$6.00M – $45.2M	$18.3M (+11%)	before first round	–	unknown	D	0%
1 Oct 2020	$16.6M	$6.05M – $45.6M	$18.5M (+11%)	before first round	–	unknown	D	0%
1 Nov 2020	$16.8M	$6.11M – $46.1M	$18.7M (+11%)	before first round	–	unknown	D	0%
1 Dec 2020	$16.9M	$6.16M – $46.5M	$18.8M (+11%)	before first round	–	unknown	D	0%
1 Jan 2021	$17.1M	$6.21M – $46.9M	$19.0M (+11%)	before first round	–	unknown	D	0%
1 Feb 2021	$17.2M	$6.27M – $47.3M	$19.2M (+11%)	before first round	–	unknown	D	0%
1 Mar 2021	$17.4M	$6.32M – $47.7M	$19.3M (+11%)	before first round	–	unknown	D	0%
1 Apr 2021	$17.5M	$6.38M – $48.2M	$19.4M (+11%)	before first round	–	unknown	D	0%
1 May 2021	$17.7M	$6.44M – $48.6M	$19.6M (+11%)	before first round	–	unknown	D	0%
1 Jun 2021	$17.8M	$6.50M – $49.0M	$19.7M (+10%)	before first round	–	unknown	D	0%
1 Jul 2021	$18.0M	$6.56M – $49.5M	$19.9M (+10%)	before first round	–	unknown	D	0%
1 Aug 2021	$18.2M	$6.62M – $49.9M	$20.0M (+10%)	before first round	–	unknown	D	0%
1 Sep 2021	$18.3M	$6.68M – $50.4M	$20.2M (+10%)	before first round	–	unknown	D	0%
1 Oct 2021	$18.5M	$6.74M – $50.8M	$20.3M (+10%)	before first round	–	unknown	D	0%
1 Nov 2021	$18.7M	$6.80M – $51.3M	$20.5M (+10%)	before first round	–	unknown	D	0%
1 Dec 2021	$18.8M	$6.86M – $51.7M	$20.6M (+9%)	before first round	–	unknown	D	0%
1 Jan 2022	$19.0M	$6.92M – $52.2M	$20.8M (+9%)	before first round	–	unknown	D	0%
1 Feb 2022	$19.2M	$6.97M – $52.6M	$20.9M (+9%)	before first round	–	unknown	D	0%
1 Mar 2022	$19.3M	$7.02M – $53.0M	$21.1M (+9%)	before first round	–	unknown	D	0%
1 Apr 2022	$19.4M	$7.07M – $53.4M	$21.2M (+9%)	before first round	–	unknown	D	0%
1 May 2022	$19.6M	$7.12M – $53.8M	$21.4M (+9%)	before first round	–	unknown	D	0%
17 May 2022	$2.5B	$1.6B – $4.9B	$3.2B (+30%)	after a round	–	unknown	B	0%
1 Jun 2022	$2.5B	$1.6B – $4.9B	$3.2B (+29%)	after a round	–	unknown	B	0%
1 Jul 2022	$2.5B	$1.6B – $4.9B	$3.2B (+26%)	after a round	–	unknown	B	0%
1 Aug 2022	$2.6B	$1.6B – $4.9B	$3.2B (+23%)	after a round	–	unknown	B	0%
1 Sep 2022	$2.7B	$1.6B – $4.9B	$3.2B (+20%)	after a round	–	unknown	B	0%
1 Oct 2022	$2.7B	$1.6B – $4.9B	$3.2B (+18%)	after a round	–	unknown	B	0%
1 Nov 2022	$2.8B	$1.6B – $4.9B	$3.2B (+15%)	after a round	–	unknown	B	0%
1 Dec 2022	$2.8B	$1.6B – $4.9B	$3.2B (+13%)	after a round	–	unknown	B	0%
1 Jan 2023	$2.9B	$1.6B – $4.9B	$3.2B (+10%)	after a round	190	unknown	B	0%
1 Feb 2023	$3.0B	$1.6B – $4.9B	$3.2B (+8%)	after a round	190	unknown	B	0%
1 Mar 2023	$3.0B	$1.6B – $4.9B	$3.2B (+6%)	after a round	190	unknown	B	0%
1 Apr 2023	$3.1B	$1.6B – $4.9B	$3.2B (+3%)	after a round	190	unknown	B	0%
1 May 2023	$3.2B	$1.6B – $4.9B	$3.2B (+1%)	after a round	190	unknown	B	0%
1 Jun 2023	$3.2B	$1.6B – $4.9B	$3.2B (0%)	after a round	190	unknown	B	0%
1 Jul 2023	$3.2B	$1.5B – $4.9B	$3.2B (0%)	after a round	190	unknown	B	0%
1 Aug 2023	$3.2B	$1.4B – $4.9B	$3.2B (0%)	after a round	190	unknown	C	0%
1 Sep 2023	$3.2B	$1.4B – $4.9B	$3.2B (0%)	after a round	190	unknown	C	0%
1 Oct 2023	$2.9B	$1.3B – $4.6B	$2.7B (-8%)	after a round	180	flat	C	27%
1 Nov 2023	$2.9B	$1.2B – $4.6B	$2.6B (-8%)	after a round	180	flat	C	27%
1 Dec 2023	$2.9B	$1.2B – $4.6B	$2.6B (-8%)	after a round	180	flat	C	27%
1 Jan 2024	$2.8B	$1.1B – $4.6B	$2.6B (-8%)	after a round	180	flat	C	27%
1 Feb 2024	$2.9B	$1.1B – $4.7B	$2.6B (-8%)	after a round	190	flat	C	25%
1 Mar 2024	$2.9B	$1.0B – $4.7B	$2.7B (-7%)	after a round	190	flat	C	23%
1 Apr 2024	$2.9B	$988M – $4.7B	$2.7B (-7%)	after a round	190	flat	C	21%
1 May 2024	$2.9B	$945M – $4.7B	$2.7B (-6%)	after a round	190	flat	C	19%
1 Jun 2024	$2.9B	$861M – $4.7B	$2.7B (-7%)	after a round	190	flat	C	18%
1 Jul 2024	$2.9B	$820M – $4.8B	$2.7B (-7%)	after a round	200	flat	C	16%
1 Aug 2024	$2.9B	$1.1B – $4.8B	$2.7B (-7%)	after a round	200	up	C	15%
1 Sep 2024	$2.9B	$1.1B – $4.8B	$2.7B (-7%)	after a round	200	up	C	14%
1 Oct 2024	$2.9B	$1.1B – $4.8B	$2.7B (-7%)	after a round	200	up	C	13%
1 Nov 2024	$2.9B	$1.1B – $4.8B	$2.7B (-8%)	after a round	200	up	C	12%
1 Dec 2024	$3.0B	$1.1B – $4.8B	$2.7B (-8%)	after a round	200	up	C	11%
1 Jan 2025	$3.0B	$1.1B – $4.8B	$2.7B (-8%)	after a round	200	up	C	10%
1 Feb 2025	$3.0B	$1.0B – $4.8B	$2.7B (-8%)	after a round	200	up	C	9%
1 Mar 2025	$3.0B	$1.0B – $4.8B	$2.7B (-8%)	after a round	200	up	C	8%
1 Apr 2025	$3.0B	$1.0B – $4.9B	$2.7B (-8%)	after a round	200	up	C	8%
1 May 2025	$3.0B	$498M – $4.9B	$2.7B (-10%)	after a round	200	flat	D	7%
1 Jun 2025	$3.0B	$473M – $4.8B	$2.7B (-10%)	after a round	200	flat	D	7%
1 Jul 2025	$3.0B	$450M – $4.8B	$2.7B (-10%)	after a round	200	flat	D	6%
1 Aug 2025	$3.0B	$428M – $4.8B	$2.7B (-9%)	after a round	204	flat	D	6%
1 Sep 2025	$3.0B	$407M – $4.7B	$2.7B (-10%)	after a round	204	flat	D	5%
11 Sep 2025	$4.0B	$2.6B – $7.9B	$5.2B (+30%)	after a round	204	flat	B	0%
1 Oct 2025	$4.1B	$2.6B – $7.9B	$5.2B (+28%)	after a round	203	flat	B	0%
1 Nov 2025	$4.1B	$2.6B – $7.6B	$5.0B (+21%)	after a round	188	flat	B	9%
1 Dec 2025	$4.2B	$2.6B – $7.6B	$5.0B (+18%)	after a round	188	flat	B	9%
1 Jan 2026	$4.3B	$2.6B – $7.6B	$5.0B (+16%)	after a round	188	flat	B	9%
1 Feb 2026	$4.3B	$2.6B – $7.3B	$4.7B (+10%)	after a round	189	flat	B	22%
1 Mar 2026	$4.3B	$2.6B – $7.3B	$4.6B (+6%)	after a round	189	flat	B	27%
1 Apr 2026	$4.4B	$2.6B – $7.3B	$4.6B (+4%)	after a round	189	flat	B	27%
1 May 2026	$4.5B	$2.6B – $7.3B	$4.6B (+2%)	after a round	194	flat	B	26%
1 Jun 2026	$4.5B	$2.6B – $7.3B	$4.5B (0%)	after a round	194	flat	B	28%
1 Jul 2026	$4.6B	$2.6B – $7.3B	$4.5B (-2%)	after a round	194	flat	B	28%
1 Aug 2026	$4.7B	$2.6B – $7.3B	$4.5B (-5%)	after a round	194	flat	B	28%
1 Sep 2026	$4.8B	$2.6B – $7.3B	$4.4B (-7%)	after a round	194	flat	B	28%
1 Oct 2026	$4.8B	$2.5B – $7.3B	$4.4B (-8%)	after a round	194	flat	B	28%
24 Oct 2026	$4.7B	$2.4B – $7.3B	$4.3B (-8%)	after a round	194	flat	B	28%

Key facts about Kriya Therapeutics

Founded: 2019
Headquarters: Morrisville, United States
Employees: about 200 +11% in a year
Total raised: $590M
Funding rounds: 2
Last round: Series D Sep 2025

Kriya Therapeutics was founded in 2019 by Fraser Wright and Shankar Ramaswamy.

Kriya Therapeutics funding history

Kriya Therapeutics has 2 funding rounds on record, from May 2022 to Sep 2025, $590M in total. None disclosed a valuation.

Series D 10 Sep 2025
Led by Patient Square Capital, Premji Invest; with Narya, T1D Fund, Founders Fund.
Sources: globenewswire.com, precisionmedicineonline.com, labiotech.eu
$320M
Series C 16 May 2022
Led by Patient Square Capital; with Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, T1D Fund, Lightswitch Capital, Narya, QVT, Transhuman Capital.
Sources: verdict.co.uk, patientsquarecapital.com, fiercebiotech.com and 3 more
$270M

Kriya Therapeutics investors

12 investors have backed Kriya Therapeutics; Patient Square Capital and Premji Invest led at least one round.

Premji Invest lead
Bluebird Ventures
Dexcel Pharma
Founders Fund
Lightswitch Capital
QVT

What Kriya Therapeutics does

Kriya Therapeutics works in biotechnology, with 9 recorded offerings and customers in healthcare, biotechnology and pharmaceuticals.

Kriya Therapeutics, Inc. is a United States biopharmaceutical company engaged in the development of gene therapies for common diseases, with a focus on ophthalmology, metabolic disease, and neurology. The company operates in therapeutic program areas and is committed to advancing gene therapy technology and making gene therapies accessible to a broader population.

Description from Veridion's company data.

Products and services

Gene Therapy Research and Development
Gene Therapy Manufacturing
Gene Therapy Clinical Trial Execution
Gene Therapy Regulatory Approval Consulting
Ophthalmology Gene Therapy Development
Metabolic Disease Gene Therapy Development
Neurology Gene Therapy Development
Investigational Gene Therapy Commercialization
Biotechnology Product Quality Assurance Services

Markets

Healthcare
Biotechnology
Pharmaceuticals

Technology

Gene Therapy

Business model

Business-to-Business
Manufacturing

Industry codes (NAICS)

541714 Research and Development in Biotechnology (except Nanobiotechnology) 70% match
325414 Biological Product (except Diagnostic) Manufacturing 30% match

Questions about Kriya Therapeutics

What is Kriya Therapeutics worth?

Valuation $4.7B (range $2.4B to $7.3B), as of 24 Oct 2026.

Has Kriya Therapeutics raised money?

Kriya Therapeutics has 2 funding rounds on record, from May 2022 to Sep 2025, $590M in total. None disclosed a valuation.

Who has invested in Kriya Therapeutics?

Patient Square Capital, Premji Invest, Narya, T1D Fund, Bluebird Ventures and CAM Capital, and 6 more. Lead investors include Patient Square Capital and Premji Invest.

How many people work at Kriya Therapeutics?

About 200, up 11% over the last year. Headcount held at about 194 from Jan 2023 to May 2026.

What does Kriya Therapeutics do?

Kriya Therapeutics works in biotechnology, with 9 recorded offerings and customers in healthcare, biotechnology and pharmaceuticals. Its main offerings are gene therapy research and development, gene therapy manufacturing and gene therapy clinical trial execution.

When was Kriya Therapeutics founded, and where is it based?

Kriya Therapeutics was founded in 2019 and is based in Morrisville, United States. It has about 200 employees, up 11% over the last year.

How we value companies Report an issue